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The biological activity of mainstream smoke from experimental kretek cigarettes with and without three
mixes of ingredients was assessed in a 90-day rat inhalation study and in a 4-day in vivo micronucleus
assay. 350 ingredients, commonly used in various combinations and in a limited number in a given brand
in the manufacture of marketed kretek cigarettes, were applied at a low and a high target level to test
cigarettes with a typical Indonesian blend of tobaccos and cloves. In the 90-day inhalation study, effects
commonly seen in rat inhalation studies with mainstream smoke were observed. In general, no ingredi-
ents-related histopathological changes were found in the respiratory tract. In the 4-day micronucleus
assay exposure of male rats to mainstream smoke from the test cigarettes containing any of the three
mixes did not increase the proportions of micronucleated cells in peripheral blood and bone marrow over
the proportion of micronucleated cells in the control group. Based on the results of these studies, it can be
concluded that the addition of ingredients commonly used in the manufacture of kretek cigarettes did not
change the overall in vivo toxicity proﬁle of the mainstream smoke.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
This publication is part of a series summarizing the in vitro and
in vivo toxicological assessment of kretek cigarettes. Smoke com-
position and biological activity of mainstream smoke (MS) from
marketed and experimental kretek cigarettes were evaluated on
a comparative basis in smoke chemistry analyses, and in vitro
and in vivo toxicity studies. The studies were designed to cover
three main topics: (1) characterization of kreteks and comparison
relative to American-blended cigarettes, (2) impact of blend type
and cloves, and (3) impact of ingredients used in kretek cigarettes.
Further in depth information of this assessment is described in the
lead publication (Roemer et al., 2014b).
The ingredients in kretek cigarettes are used to facilitate
tobacco processing, to preserve tobacco, and to complement the
subjective taste characteristics of smoke and are similar to those
used in conventional American-blended cigarettes.Ingredients used in conventional American-blended cigarettes
have been assessed for their biological activity and toxicity proﬁles
using the test strategy described byDempsey et al. (2011). The stan-
dard assay battery for the testing of cigarette MS in general has
included analyses for the chemical composition of cigarette smoke,
an in vitro test battery consisting of a cytotoxicity assay (i.e., the
Neutral Red Uptake assay with BALB/c 3T3 cells), a bacterial muta-
genicity assay (i.e., the Salmonella Reverse Mutation assay), a mam-
malian cell genotoxicity assay (i.e., the mouse lymphoma assay), an
in vivo rat micronucleus assay, and a 90-day rat inhalation study
(Carmines and Gaworski, 2005; Carmines et al., 2005; Gaworski
et al., 2008a,b, 2009; Roemer et al., 2002; Rustemeier et al., 2002;
Schramke et al., 2006; Vanscheeuwijck et al., 2002). Ingredients
added to American-blended cigarettes have been assessed as single
ingredients applied to experimental cigarettes at different inclusion
levels or multiple ingredients have been tested in mixes, usually as
well at different inclusion levels in the experimental cigarettes (for
an overview on cigarette ingredient studies, see Dempsey et al.,
2011).
The study described here was designed to evaluate the impact of
three different mixes of ingredients on the in vivo biological activity
of MS of kretek cigarettes. Following the standard testing strategy
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ﬁller of typical American-blended cigarettes (e.g., Carmines, 2002;
Carmines and Gaworski, 2005; Carmines et al., 2005; Dempsey
et al., 2011; Gaworski et al., 2008b, 2011; Vanscheeuwijck et al.,
2002) the in vivo test battery included a 90-day inhalation study
and a 4-day micronucleus assay in rats. For the 90-day inhalation
study the Organisation for Economic Co-operation and Develop-
ment (OECD) guideline 413 (OECD, 1981) was followed in principle
with the following deviation for practical limitations: two concen-
trations of each ingredient at a low and high target level were tested
instead of the recommended three concentrations. For the micro-
nucleus assay, the protocol of the OECD guideline 474 (OECD,
1997) was followed including analysis of micronucleated polychro-
matic erythrocytes in the bone marrow and enumeration of CD-71-
positive erythrocytes (reticulocytes) in peripheral blood after
4 days of smoke exposure via inhalation. Data on detailed smoke
chemistry and in vitro assays for mutagenicity/genotoxicity and
for cytotoxicity of the experimental kretek cigarettes are presented
in another publication of this series (Roemer et al., 2014a).2. Materials and methods
2.1. General
Detailed descriptions regarding the chemical analyses, toxico-
logical assays and statistical procedures can be found in the ﬁrst
of this series of publications (Roemer et al., 2014b).
2.2. Cigarettes
A total of 350 ingredients, commonly used in various combina-
tions and in a limited number in a given brand in the manufacture
of marketed kretek cigarettes, were assigned to three different
ingredient mixes, i.e., Mix A, Mix B, and Mix C. Each ingredient
was introduced in the respective mixes at a low or a high target
level. The low levels approximate to the typical use levels in kretek
cigarettes, the high levels were 2.5 (licorice extract and invert
sugar) or 3 times the low levels. The list of tested ingredients, their
regulatory status, and the target concentrations in each mix are
given in Roemer et al. (2014a) in the Appendix in Table A. In some
cases ingredients were applied to more than one mix because of
the way the ingredient is typically added during the manufacturing
process. Each ingredient was of food grade quality. The ingredients
were added to the kretek ﬁller, i.e., tobacco and cloves, during the
cigarette manufacturing process. The point of addition during the
manufacturing process was chosen to closely mimic actual pro-
cesses in the factory. The experimental cigarettes were constructed
to minimize differences in cigarette tar yield and puff count. The
cigarettes were manufactured to a constant weight, comprising
69% Indonesian tobacco and 31% cut cloves, where addition of
ingredients displaced tobacco and cloves thereby reducing their
weight relative to the control cigarette. The control cigarette was
of identical construction and made with the same tobacco and
clove blend as the test cigarettes but without the addition of ingre-
dients. The humectants propylene glycol, glycerin, and D-sorbitol
were added to all cigarettes, i.e., control and test cigarettes. Further
details on the cigarettes can be found in Roemer et al. (2014a) in
Table 1. The reference cigarette 2R4F was used as internal refer-
ence in the studies.
2.3. Animal treatments
The inhalation studies were conducted in an AAALAC-accredited
facility (Association for Assessment and Accreditation of Laboratory
Animal Care International, 2006) in Leuven, Belgium (Philip MorrisResearch Laboratories) where the care and use of rats was con-
formed to the American Association for Laboratory Animal Science
Policy (www.aalas.org). The studies were approved by the local
Institutional Animal Care and Use Committee according to Belgian
legislation. They were conducted in compliance with the OECD
Principles on Good Laboratory Practice (GLP) (as revised in 1997).
For the 90-day inhalation study according to the OECD guide-
line 413 (OECD, 1981), the animals were randomized to the differ-
ent treatment groups and exposed nose-only in ﬂow-pass glass
inhalation tubes to a target total particulate matter (TPM) concen-
tration of 200 lg/l for 6 h/day, 7 days/week, for 90 days. Following
the OECD guideline, each group contained 10 male and 10 female
rats. The rats were individually identiﬁed by means of a subcutane-
ous transponder. A post-inhalation period of 42 days was included
for satellite animals (10 per group and gender) to investigate
reversibility, persistence, and delayed occurrence of smoke- and/
or ingredients-related effects. Assessed biological endpoints were
according to OECD guideline 413, with special emphasis on histo-
pathology of the respiratory tract as outlined in Roemer et al.
(2014b). Details on the methodology have also been described in
Vanscheeuwijck et al. (2002).
For the in vivo micronucleus assay according to OECD guideline
474 (OECD, 1997), male rats, 8 animals per group, were exposed
nose-only to a target TPM concentration of 720 lg/l or to ﬁltered,
conditioned air (sham exposure group) on 4 consecutive days.
2.4. Statistical analyses used for the 90-day inhalation study and the
4-day in vivo micronucleus assay
All groups exposed to MS from the test cigarettes containing
either of the three different mixes of ingredients at a low or a high
target level were compared to the group exposed to MS of the con-
trol cigarette containing no ingredient mixes and all smoke-
exposed groups to the sham-exposed group.
The reference cigarette 2R4F was only used as an internal refer-
ence to monitor consistency with historical data of the laboratory
and was not included in the statistical evaluation of the control and
test cigarettes.3. Results
3.1. 90-day inhalation study
3.1.1. Test atmosphere characterization
Analysis of the test atmospheres throughout the 90-day inhala-
tion period indicated that the target TPM concentration of 200 lg/l
was achieved for all smoke-exposed groups (Table 1). Generation
of the smoke and its delivery to the exposure chambers were
reproducibly performed as evidenced by relative standard devia-
tions not exceeding 7% for TPM and carbon monoxide (CO) concen-
trations throughout the inhalation period.
The particle size distribution measurements indicated that par-
ticles were equally respirable in all smoke-exposed groups; the
mass median aerodynamic diameter (MMAD) ranged from 0.85
to 0.89 lm (geometrical standard deviation (GSD) from 1.71 to
1.75) in the smoke from the control and test cigarettes. Nicotine,
eugenol, and aldehyde concentrations in the test atmospheres
were similar for the control and test cigarettes. A detailed analysis
on the smoke chemistry of these cigarettes is given in Roemer et al.
(2014a).
3.1.2. Internal reference cigarette 2R4F
The test atmosphere characteristics for the reference cigarette
2R4F were in agreement with those determined in former studies
(data not shown). Qualitatively, the biological effects observed in
Table 1
Test atmosphere in exposure chamber of the 90-day inhalation study (medians or mean ± standard deviation).
Groupa TPMb (lg/l)
(Nc = 93)
Particle sized Eugenol
(lg/l) (N = 6)
Nicotine (lg/l)
(N = 9–17)
Carbon monoxide
(ppm) (N = 92–93)
Acetaldehyde
(lg/l) (N = 11–12)
Acrolein (lg/l)
(N = 11–12)
Formaldehyde
(lg/l) (N = 11–12)
MMADe(lm) GSDf
Sham <1.6 – – – – <4.5 – – –
Control 195.3 ± 8.2 0.86 1.72 20.0 ± 2.1 14.9 ± 1.4 133.4 ± 6.3 5.91 ± 0.38 0.74 ± 0.04 0.36 ± 0.03
Mix A low 196.2 ± 8.4 0.89 1.71 21.2 ± 1.6 13.7 ± 1.7 134.7 ± 9.7 5.50 ± 0.70 0.70 ± 0.09 0.34 ± 0.05
Mix A high 197.4 ± 8.2 0.85 1.71 20.7 ± 3.5 12.8 ± 1.4 126.0 ± 4.9 5.52 ± 0.42 0.70 ± 0.06 0.40 ± 0.04
Mix B low 200.1 ± 10.6 0.86 1.71 22.3 ± 2.1 14.2 ± 2.0 130.1 ± 6.0 5.84 ± 0.32 0.74 ± 0.03 0.39 ± 0.03
Mix B high 197.0 ± 9.7 0.89 1.75 22.7 ± 1.8 12.4 ± 1.5 124.4 ± 6.3 5.50 ± 0.53 0.69 ± 0.07 0.37 ± 0.04
Mix C low 198.5 ± 11.5 0.85 1.74 19.9 ± 2.2 14.3 ± 3.1 132.5 ± 8.4 5.78 ± 0.48 0.72 ± 0.07 0.36 ± 0.04
Mix C high 199.2 ± 9.6 0.86 1.72 21.5 ± 2.1 14.4 ± 1.4 133.3 ± 8.4 5.28 ± 0.74 0.67 ± 0.08 0.37 ± 0.04
a Low and high = level of ingredients in respective ingredients mix.
b TPM, Total particulate matter.
c N, number of determinations.
d N = 2, except for Mix C low and Mix C high, where N = 1.
e MMAD, Mass median aerodynamic diameter.
f GSD, Geometric standard deviation.
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with historical data from previous studies (data not shown).
3.1.3. Respiratory physiology
There were no indications that the inclusion of the different
ingredient mixes in the test cigarettes affected the measured
respiratory physiology parameters. Respiratory frequencies, tidal
volumes, respiratory minute volumes, and peak inspiratory ﬂows
were not statistically signiﬁcantly different for the male and
female groups exposed to MS from the test cigarettes when com-
pared to the control cigarette groups.
3.1.4. Carboxyhemoglobin
In the smoke-exposed groups, the mean steady-state blood car-
boxyhemoglobin concentration ranged between 13% and 15% in
male rats, and between 14% and 17% in female rats. There were
no indications that MS from the test cigarettes with low or high
levels of the three mixes of ingredients had an effect on the
steady-state carboxyhemoglobin concentrations in male and
female rats compared to the smoke-exposed control groups.
3.1.5. Urinary nicotine metabolites
The amount of nicotine metabolites (nornicotine, norcotinine,
30-hydroxycotinine, cotinine, and nicotine-N0-oxide) excreted in
urine indicated that the rats were exposed to smoke and that the
inclusion of the ingredient mixes in the test cigarettes did not
appear to affect total nicotine absorption and metabolism. As seen
in general, there was some variation in the total amount of nicotine
metabolites recovered in the urine from rats in the different
groups, but there were no clear patterns that could be attributed
to inclusion of the ingredient mixes because there was no apparent
ingredients level-related response. There is a good concordance
between the total nicotine metabolites excreted in urine and the
concentration of nicotine in the test atmosphere for all smoke-
exposed male and female rat groups (Fig. 1).
The urinary nicotine metabolites data, together with the results
of the respiratory parameters and blood carboxyhemoglobin con-
centrations, indicated a comparable uptake of the MS generated
from the different experimental kretek cigarettes.
3.1.6. Clinical observations
After daily exposure, Harderian gland secretion and wet fur
were frequently observed in sham- and smoke-exposed groups,
incidences in the smoke-exposed groups were higher than in the
sham-exposed groups. Sporadically, nasal discharge and closed
eyelids were seen, altered levels of activity, increased irritability,
decreased gripping ability and decreased turning reﬂex were alsoobserved. All of these observations have also been observed in pre-
vious rat inhalation studies with cigarette smoke (e.g.,
Vanscheeuwijck et al., 2002) and are known to be related to tube
restraint and/or the irritative capacity of cigarette smoke. There
were no differences that could clearly be related to the different
exposure groups. During the post-inhalation period, there were
no toxicologically relevant ﬁndings.
3.1.7. Body weight and food consumption
Body weight gain was not affected by inclusion of the three
ingredient mixes at a low or a high level in the test cigarettes when
compared to control cigarettes during the 90-day inhalation period
and the 42-day post-inhalation period in male and female rats
(Fig. 2). Body weight was statistically signiﬁcantly lower in male
rats exposed to MS relative to sham-exposed rats at the end of
the 90-day inhalation period. During the post-inhalation period,
all groups of male smoke-exposed rats demonstrated an increased
rate of body weight gain and at the end of the post-inhalation per-
iod, the body weight of the male smoke-exposed rats was not dif-
ferent from that of the sham-exposed rats. There was no impact on
body weight gain in smoke-exposed female rats. These effects on
body weight development in male and female rats have been pre-
viously observed in other inhalation studies with cigarettes
(Coggins et al., 1989, 1993; Kinsler et al., 2003; Terpstra et al.,
2003; Vanscheeuwijck et al., 2002). Over the course of the study,
the mean food consumption relative to body weight for all
smoke-exposed groups was comparable to the sham-exposed
group in both sexes. No ingredients type- or ingredients level-
dependent effects were observed.
3.1.8. Clinical chemistry
After the 90-day inhalation period, typical smoke-exposure-
induced changes of the clinical chemistry parameters were
observed in male and female rats. These included increased activ-
ities of the liver enzymes alanine aminotransferase, alkaline phos-
phatase, and aspartate aminotransferase, decreased serum
concentrations of proteins, triglycerides, cholesterol and a
decreased albumin proportion. These ﬁndings have been observed
in previous studies (e.g., Terpstra et al., 2003; Vanscheeuwijck
et al., 2002). In all female smoke-exposed groups, there was also
a trend towards increased urea concentrations and decreased cal-
cium concentrations when compared to the sham-exposed group.
After the post-inhalation period, most smoke-exposure-induced
effects showed a reversal.
In general, the clinical chemistry results were not indicative of
adverse effects related to the addition of any of the ingredient
mixes to the kretek ﬁller of the test cigarettes, as evidenced by
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Fig. 1. Total amount of nicotine metabolites excreted in urine, sample collection
over 24 h, determined once during the 90-day inhalation period (mean ± standard
error, N = 8 rats per group) from male (A) and female (B) rats and nicotine
concentration in test atmosphere (mean ± standard deviation, N = 17 determina-
tions during the 90-day inhalation period, except for Mix A low and Mix A high
N = 15, Mix B high N = 16, Mix C high N = 9).
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test cigarette groups when compared to the control group after the
90-day inhalation period and the 42-day post-inhalation period.
3.1.9. Hematology
After the inhalation and post-inhalation periods, no statistically
signiﬁcant differences of the smoke-exposed test cigarette groups
compared to the control cigarette group were observed for red
and white blood cell parameters and the differential white blood
cell count in male and female rats, with only a few exceptions.
Decreases and increases were occasionally statistically signiﬁ-
cantly different, but in the range of those found in the sham-
exposed groups, in the range of the other smoke-exposed groups
or in the historical range as found in previous inhalation studies.
3.1.10. Organ weights
There were slight but statistically signiﬁcant changes in the rel-
ative weight (organ weight relative to exsanguinated body weight)
of certain organs, including testis, spleen, adrenals, kidney, liver,
thymus, larynx with trachea, lung, and brain in all smoke-exposed
groups relative to sham-treated animals at the end of the 90-day
inhalation period. Neither of these ﬁndings is considered adverse
and they were either incidental or a general response to smoke
exposure.
There were no statistically signiﬁcant differences in organ
weights (absolute and relative), including kidney, adrenal, testis,
spleen, liver, thymus, brain, larynx with trachea, and lung at the
end of the 90-day inhalation period or at the end of the 42-day
post-inhalation period between the groups exposed to MS of any
of the test cigarettes compared to the smoke-exposed control cig-
arette groups.
3.1.11. Histopathology
Histopathological examination of the respiratory tract organs
revealed tissue alterations characteristic for exposure to MS from
American-blended cigarettes in rats in inhalation studies when
compared to sham-exposed rats (e.g., Vanscheeuwijck et al.,
2002). In Table 2 (males) and Table 3 (females) only histopatholo-
gical endpoints that are responsive to MS, i.e., statistically signiﬁ-
cantly different to sham-exposed rats, are given. At the end of
the 90-day inhalation period, histopathological changes observed
in the nasal epithelia included hyperplasia, squamous metaplasia,
loss of goblet cells, and goblet cell hyperplasia in the respiratory
epithelium, and squamous metaplasia and atrophy of the olfactory
epithelium. In the larynx, squamous epithelial hyperplasia and
squamous metaplasia of the pseudostratiﬁed epithelium, and at
the tracheal bifurcation squamous metaplasia of the respiratory
epithelium were noted. Hyperplasia of goblet cells of the left main
bronchus, hyperplasia of alveolar epithelium (pneumocytes), alve-
olar histiocytosis (unpigmented and pigmented macrophages),
presence of pigmented macrophage nests, general inﬂammation,
and focal/multifocal emphysematous alterations (also found in
sham-exposed rats) were noted for the lung.
Histopathological ﬁndings as listed above differed with regard
to incidence and severity at the different levels of the respiratory
tract investigated. In general, there were no statistically signiﬁcant
differences between the rats exposed to MS from the test cigarettes
as compared to those exposed to smoke from the control cigarette
at the end of the 90-day exposure period. The limited number of
statistically signiﬁcant differences observed were sporadic and
inconsistent.
Statistically signiﬁcantly lower severities compared to the con-
trol group were observed mainly in female rats exposed to MS of
Mix A cigarettes: in the nose (atrophy of the olfactory epithelium
for Mix A low level cigarettes) and the larynx (squamous epithelial
metaplasia, amount of corniﬁcation of the metaplastic cuboidalepithelium and at the vocal folds for Mix A high level cigarettes).
The ﬁnding of a lower amount of corniﬁcation of the metaplastic
cuboidal epithelium in the larynx was also seen in male rats
exposed to MS from Mix A or Mix C test cigarettes (both at low
and high level of ingredient mixes added).
For the rats exposed to MS from Mix B or Mix C test cigarettes,
statistically signiﬁcantly higher responses as compared to the con-
trol groups were only found for a few endpoints and in the female
rats only. A higher severity was observed in the respiratory region
of the nose level 1 (amount of corniﬁcation at the metaplastic
respiratory epithelium and the amount of exudate in the nasal cav-
ity) for the Mix B (low level) and Mix C (low and high level) groups.
Although not signiﬁcantly different, inﬂammatory cell inﬁltration
at the respiratory epithelium at this nose level was also higher in
these groups. With respect to the amount of corniﬁcation of the
metaplastic respiratory epithelium, the absolute increase in sever-
ity compared to the control cigarette group was limited and no
ingredients-level-dependent effect could be observed in the female
Mix C groups. With respect to exudate in the nasal cavity level 1,
the absolute increase in severity compared to the control cigarette
group was moderate (increase in mean score up to 1.4); an ingre-
dients-level-dependent effect in the female Mix C groups was
observed.
At nose level 4, the inﬂammatory cell inﬁltration of the lamina
propria of the paradental squamous epithelium of the gingiva at
the region of the molar teeth was statistically signiﬁcantly higher
in the female rats exposed to smoke fromMix B high level cigarettes
Fig. 2. Mean body weights of male (A) and female (B) rats exposed to fresh air
(sham) and MS of the control and test cigarettes (RSD% <16% for male rats and 13%
for female rats) during the 90-day inhalation study.
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amount of inﬂammatory cell inﬁltration was not statistically signif-
icantly different when compared to the corresponding sham-
exposed group. This ﬁnding was also present to the same extent
in male and female sham-exposed rats after the post-inhalation
period. As such, this ﬁnding was considered not to be directly
smoke-related.
Female rats exposed to MS from the Mix B low level cigarettes
showed a statistically signiﬁcantly higher degree of hyperplasia of
the squamous epithelium at the lower medial region of the vocal
cords in the larynx as compared to the control cigarette group.
However, as there was no statistical difference in the female rats
exposed to MS from Mix B high level cigarettes as such, this was
considered an incidental ﬁnding. Female rats of the Mix C high
level group showed a statistically signiﬁcantly higher degree of
squamous epithelial metaplasia without corniﬁcation at the tra-
cheal bifurcation as compared to the control group, this was as
well considered a chance ﬁnding.
After the 42-day post-inhalation period, all smoke-induced
effects showed partial or complete reversal in male and female
rats. For the Mix A high level group, no statistically signiﬁcant dif-
ferences were found when compared to the control cigarette
group, except for reserve cell hyperplasia at the respiratory region
and loss of goblet cells at nose level 1 which both were higher in
female rats when compared to the control cigarette group. The
responses in the Mix B and Mix C high level groups were equal
to or lower when compared to the control group except for the
squamous epithelial metaplasia of the upper medial region of the
vocal cords at the larynx in male rats of the Mix C high level groupwhich was statistically signiﬁcantly more pronounced when com-
pared to the control cigarette group. The above-mentioned ﬁndings
after the 42-day post-inhalation period were considered incidental,
not ingredients-related ﬁndings.
Histopathological examination of non-respiratory organs at
both the end of the inhalation and post-inhalation period revealed
no new effects, especially no systemic or organ-related toxicity due
to the addition of the three ingredient mixes at a low or a high level
to the kretek ﬁller beyond the typical American-blended cigarette-
MS related ﬁndings (data not shown).3.2. Micronucleus assay
Analysis of the test atmospheres throughout the 4-day inhala-
tion period indicated that the target TPM concentration of
720 lg/l was achieved for all smoke-exposed groups (mean of
TPM concentrations ranged from 678 to 719 lg/l). The mean CO
concentration in the test atmospheres ranged from 411 to
449 ppm for the control and test cigarettes. Generation of the MS
and its delivery to the exposure chambers were reproducibly per-
formed as evidenced by relative standard deviations not exceeding
9% for TPM and CO concentrations throughout the 4 days of inha-
lation. Nicotine, eugenol, and aldehyde concentrations in the test
atmospheres were similar for the control and test cigarettes as
seen before for the 90-day inhalation study (data not shown).
The mean body weights of all rats were similar at the start of the
study, ranging from 266 to 270 g per rat.
Rats exposed to MS from the control and test cigarettes contain-
ing the three different ingredient mixes at a low or a high level
showed no increased proportions of micronucleated reticulocytes
in peripheral blood and no increased proportions of micronucleat-
ed polychromatic erythrocytes in bone marrow when compared to
sham-exposed rats (Fig. 3). Moreover, there were no statistically
signiﬁcant differences in the proportion of micronucleated reticu-
locytes and in the proportion of micronucleated polychromatic
erythrocytes in the groups exposed to MS from the test cigarettes
compared to the control cigarette group. The reference cigarette
2R4F group did not show any signiﬁcant increase in the
micronucleated reticulocytes and micronucleated polychromatic
erythrocytes frequency as compared to the sham-exposed group
(data not shown). There was no indication of cytotoxicity caused
by the inhalation of MS as evidenced by the proportion of
reticulocytes in the peripheral blood and by the proportion of
polychromatic erythrocytes in bone marrow as compared to
sham-exposed rats. The proportion of micronuclei in rats treated
intraperitoneally with the positive control cyclophosphamide
(CPA, 15 mg/kg bodyweight for 45–49 h) was statistically signiﬁ-
cantly higher than in the sham-exposed group and there was
higher cytotoxicity in the CPA-treated group when compared to
the sham-exposed group. The mean CPA-induced proportion
of micronucleated reticulocytes in peripheral blood and of
micronucleated polychromatic erythrocytes in bone marrow was
2.3 ± 0.17% and 0.963 ± 0.15%, respectively, with an induced
cytotoxicity of approximately 50%. The observed increases in
micronuclei frequencies for CPA were comparable to those seen
in previous studies (Carmines and Gaworski, 2005; Carmines
et al., 2005; Gaworski et al., 2008b; Van Miert et al., 2008) and
conﬁrmed the performance and validity of the study.4. Discussion
In this study ingredients commonly used in the manufacture of
kretek cigarettes to facilitate tobacco processing, to preserve
tobacco, and to impart brand ﬂavor to smoke were assessed for
their possible impact on the in vivo biological activity of MS of test
Table 2
Histopathological ﬁndings in the respiratory tract of male rats after the 90-day inhalation period to MS of the control and test cigarettes (mean score ± standard error and
incidence).
Localization Tissue type Observation Control Mix A
low
Mix A
high
Mix B
low
Mix B
high
Mix C
low
Mix C
high
Nose level 1 Respiratory epithelium Reserve cell hyperplasia 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Goblet cell hyperplasia 0.9 ± 0.0 0.8 ± 0.1 0.8 ± 0.3 0.7 ± 0.2 1.3 ± 0.3 0.8 ± 0.3 1.2 ± 0.2
6/10 8/10 5/10 6/10 8/10 5/8 9/10
Loss of goblet cells 3.2 ± 0.3 3.6 ± 0.2 2.4 ± 0.3 2.7 ± 0.3 2.8 ± 0.2 2.8 ± 0.3 2.9 ± 0.3
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Squamous metaplasia with
corniﬁcation
0.7 ± 0.2 1.0 ± 0.0 0.8 ± 0.1 0.6 ± 0.2 1.0 ± 0.0 0.9 ± 0.1 0.8 ± 0.1
7/10 10/10 8/10 6/10 10/10 7/8 8/10
Squamous metaplasia without
corniﬁcation
4.0 ± 0.0 4.0 ± 0.0 3.8 ± 0.2 4.0 ± 0.0 4.0 ± 0.0 3.5 ± 0.5 3.6 ± 0.4
10/10 10/10 10/10 10/10 10/10 7/8 9/10
Lamina propria Inﬂammatory cell inﬁltration 2.2 ± 0.2 2.6 ± 0.4 1.9 ± 0.4 2.3 ± 0.4 2.0 ± 0.3 1.6 ± 0.3 2.1 ± 0.3
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Lumen Exudate 1.5 ± 0.5 2.0 ± 0.5 0.8 ± 0.5 1.3 ± 0.4 1.4 ± 0.4 0.5 ± 0.2 1.6 ± 0.4
8/10 8/10 8/10 7/10 8/10 4/8 9/10
Nose level 2 Respiratory epithelium Reserve cell hyperplasia 1.2 ± 0.5 1.0 ± 0.4 0.3 ± 0.2 0.1 ± 0.1 0.7 ± 0.4 1.0 ± 0.5 1.8 ± 0.5
4/10 5/10 2/10 1/10 3/10 3/8 8/10
Olfactory epithelium Atrophy 1.6 ± 0.6 1.0 ± 0.4 1.8 ± 0.5 0.8 ± 0.3 0.7 ± 0.3 3.1 ± 0.6 1.5 ± 0.5
5/10 5/10 7/10 4/10 4/10 7/8 7/10
Squamous metaplasia without
corniﬁcation
0.8 ± 0.5 0.4 ± 0.4 1.0 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 2.3 ± 0.7 0.8 ± 0.5
2/10 1/10 3/10 0/10 0/10 5/8 2/10
Lamina propria Loss of nerve bundles 0.5 ± 0.3 0.3 ± 0.3 0.3 ± 0.2 0.2 ± 0.1 0.1 ± 0.1 1.1 ± 0.4 0.2 ± 0.2
3/10 1/10 2/10 2/10 1/10 5/8 1/10
Larynx Ventral depression Squamous metaplasia without
corniﬁcation
3.8 ± 0.5 3.0 ± 0.4 3.1 ± 0.5 3.9 ± 0.3 3.3 ± 0.5 2.5 ± 0.6 2.6 ± 0.6
10/10 10/10 10/10 10/10 9/10 7/8 9/10
Squamous metaplasia with
corniﬁcation
2.1 ± 0.7 0.0 ± 0.0 0.6 ± 0.5 0.7 ± 0.5 0.9 ± 0.5 0.0 ± 0.0 0.2 ± 0.1
7/10 0/10⁄⁄ 2/10⁄ 3/10 3/10 0/8⁄⁄ 2/10⁄
Vocal cords, lower medial
region
Hyperplasia without corniﬁcation 2.0 ± 0.2 2.0 ± 0.2 1.7 ± 0.2 2.2 ± 0.2 2.0 ± 0.3 1.6 ± 0.2 2.0 ± 0.1
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Hyperplasia with corniﬁcation 4.6 ± 0.2 3.7 ± 0.5 4.1 ± 0.5 4.6 ± 0.2 4.0 ± 0.6 3.1 ± 0.8 4.0 ± 0.6
10/10 10/10 9/10 10/10 9/10 6/8 9/10
Vocal cords, upper medial
region
Squamous metaplasia without
corniﬁcation
4.8 ± 0.1 4.7 ± 0.2 4.5 ± 0.2 4.7 ± 0.2 4.7 ± 0.2 4.3 ± 0.2 4.7 ± 0.2
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Squamous metaplasia with
corniﬁcation
3.5 ± 0.5 3.8 ± 0.5 2.1 ± 0.4 3.3 ± 0.5 3.1 ± 0.5 2.0 ± 0.5 3.4 ± 0.6
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Pseudo-stratiﬁed
epithelium
Squamous metaplasia without
corniﬁcation
5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Squamous metaplasia with
corniﬁcation
5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Vocal folds Squamous epithelium Hyperplasia without corniﬁcation 1.4 ± 0.3 1.0 ± 0.0 1.2 ± 0.1 1.0 ± 0.0 1.3 ± 0.2 1.1 ± 0.1 1.3 ± 0.2
10/10 10/10 10/10 10/10 10/10 8/8 10/10
Hyperplasia with corniﬁcation 4.2 ± 0.4 3.1 ± 0.6 3.4 ± 0.6 3.8 ± 0.5 3.2 ± 0.7 2.8 ± 0.4 3.5 ± 0.5
10/10 10/10 9/10 10/10 9/10 8/8 10/10
Tracheal
bifurcation
Respiratory epithelium Goblet cell hyperplasia 0.2 ± 0.1 0.1 ± 0.1 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.6 ± 0.2 0.1 ± 0.1
2/10 1/10 3/10 2/10 2/10 5/8 1/10
Squamous metaplasia without
corniﬁcation
1.4 ± 0.6 2.5 ± 0.6 2.2 ± 0.6 1.4 ± 0.6 1.0 ± 0.5 0.4 ± 0.2 1.2 ± 0.5
4/10 7/10 6/10 4/10 3/10 3/8 4/10
Left lung Respiratory epithelium Goblet cell hyperplasia 1.5 ± 0.3 1.3 ± 0.5 0.7 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 2.0 ± 0.7 1.0 ± 0.3
8/10 7/10 4/10 7/10 7/10 6/8 6/10
Alveoli Alveolar macrophages without
pigmentation
1.0 ± 0.0 1.0 ± 0.0 0.9 ± 0.1 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
10/10 10/10 9/10 10/10 10/10 8/8 10/10
Alveolar macrophages with
pigmentation
1.2 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.4 ± 0.2 1.0 ± 0.0 1.1 ± 0.1 1.3 ± 0.2
10/10 9/10 9/10 10/10 10/10 8/8 10/10
Emphysema 1.1 ± 0.1 1.3 ± 0.3 1.0 ± 0.0 1.3 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.0
10/10 9/10 10/10 10/10 9/10 8/8 10/10
Remarks: Only endpoints are shown that are responsive to MS when compared to the fresh air (sham) exposed rats. Comparison to control: * and ** indicate statistically
different to control cigarette group, p 6 0.05 and p 6 0.01, respectively.
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high target level. MS from control cigarettes with the same blend
composition as the test cigarettes was used for comparison.
The two OECD in vivo assays, i.e., a 90-day rat inhalation study
and a 4-day in vivo micronucleus assay in rats, were used as
described in previous studies for the assessment of ingredients
used in the manufacture of American-blended cigarettes
(Dempsey et al., 2011).
Throughout the 90-day and 4-day inhalation period, the results
of the determination of constituents in the diluted MS, such asnicotine, eugenol, CO, and various aldehydes, indicated a constant
smoke generation and achievement of target smoke concentrations
for control and test cigarettes. Measurement of respiratory param-
eters, blood carboxyhemoglobin concentrations, and urinary nico-
tine metabolites indicated a comparable uptake of the diluted MS
between the control and the test cigarettes groups. There were
no remarkable differences in clinical observations, food consump-
tion, body weight, clinical chemistry, and gross pathology, nor
were there differences seen for smoke-related hematological
changes between the control and test cigarette groups. Typical
Table 3
Histopathological ﬁndings in the respiratory tract of female rats after the 90-day inhalation period to mainstream smoke of the control and test cigarettes (mean score ± standard
error and incidence).
Localization Tissue type Observation Control Mix A
low
Mix A
high
Mix B
low
Mix B
high
Mix C
low
Mix C
high
Nose level 1 Respiratory epithelium Reserve cell hyperplasia 4.0 ± 0.0
0/0
4.0 ± 0.0
0/0
4.0 ± 0.0
0/0
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
Goblet cell hyperplasia 0.6 ± 0.2
6/10
0.3 ± 0.2
3/9
0.4 ± 0.2
4/10
0.3 ± 0.2
3/10
0.6 ± 0.2
5/10
0.4 ± 0.2
4/10
0.5 ± 0.2
5/10
Loss of goblet cells 3.3 ± 0.2
10/10
3.8 ± 0.2
9/9
3.6 ± 0.2
10/10
3.8 ± 0.2
10/10
3.2 ± 0.2
10/10
3.9 ± 0.2
10/10
3.5 ± 0.3
10/10
Squamous metaplasia with
corniﬁcation
0.7 ± 0.2
7/10
0.6 ± 0.2
5/9
1.0 ± 0.1
9/10
1.2 ± 0.1
10/10⁄
0.9 ± 0.1
9/10
1.1 ± 0.1
10/10⁄
1.1 ± 0.1
10/10⁄
Squamous metaplasia without
corniﬁcation
4.0 ± 0.0
10/10
4.0 ± 0.0
9/9
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
4.0 ± 0.0
10/10
Lamina propria Inﬂammatory cell inﬁltration 2.3 ± 0.3
10/10
2.0 ± 0.2
9/9
1.8 ± 0.2
10/10
2.5 ± 0.3
10/10
2.0 ± 0.3
10/10
2.5 ± 0.3
10/10
2.7 ± 0.3
10/10
Lumen Exudate 0.8 ± 0.4
5/10
1.0 ± 0.3
5/9
1.0 ± 0.4
5/10
2.0 ± 0.3
9/10⁄
1.2 ± 0.4
6/10
1.9 ± 0.3
9/10⁄
2.2 ± 0.3
9/10⁄
Nose level 2 Respiratory epithelium Reserve cell hyperplasia 1.1 ± 0.5
4/10
1.0 ± 0.5
4/9
0.7 ± 0.4
3/10
2.0 ± 0.6
7/10
0.4 ± 0.2
3/10
1.7 ± 0.4
8/10
1.8 ± 0.5
7/10
Olfactory epithelium Atrophy 2.5 ± 0.6
8/10
2.1 ± 0.5
8/9
1.8 ± 0.5
7/10
2.8 ± 0.5
8/10
1.9 ± 0.6
8/10
2.4 ± 0.7
7/10
3.7 ± 0.4
10/10
Squamous metaplasia without
corniﬁcation
1.8 ± 0.6
5/10
0.7 ± 0.5
2/9
0.8 ± 0.5
2/10
2.2 ± 0.6
6/10
1.0 ± 0.5
3/10
1.7 ± 0.6
5/10
2.3 ± 0.5
8/10
Lamina propria Loss of nerve bundles 1.3 ± 0.5
5/10
0.7 ± 0.4
3/9
0.7 ± 0.4
3/10
1.4 ± 0.4
6/10
0.8 ± 0.5
3/10
1.4 ± 0.5
5/10
2.1 ± 0.4
8/10
Nose level 3 Olfactory epithelium Atrophy 2.0 ± 0.6
6/10
0.2 ± 0.2
1/9⁄
0.6 ± 0.4
2/10
1.7 ± 0.6
5/10
1.4 ± 0.6
4/10
1.4 ± 0.6
4/10
1.4 ± 0.5
5/10
Squamous metaplasia without
corniﬁcation
1.4 ± 0.6
4/10
0.0 ± 0.0
0/9
0.4 ± 0.4
1/10
1.4 ± 0.6
4/10
1.2 ± 0.6
3/10
1.2 ± 0.6
3/10
0.4 ± 0.4
1/10
Larynx Ventral depression Squamous metaplasia without
corniﬁcation
4.8 ± 0.1
10/10
4.1 ± 0.4
9/9
2.8 ± 0.6
10/10⁄
3.5 ± 0.6
10/10
4.2 ± 0.4
10/10
4.6 ± 0.3
10/10
4.3 ± 0.5
10/10
Squamous metaplasia with
corniﬁcation
3.1 ± 0.8
7/10
1.1 ± 0.7
2/9
0.5 ± 0.5
1/10⁄⁄
1.5 ± 0.7
4/10
1.8 ± 0.7
5/10
1.9 ± 0.7
7/10
1.2 ± 0.5
5/10
Vocal cords, lower medial
region
Hyperplasia without corniﬁcation 1.5 ± 0.2
10/10
1.9 ± 0.1
9/9
1.7 ± 0.2
9/10
2.1 ± 0.1
10/10⁄⁄
1.8 ± 0.2
10/10
1.8 ± 0.2
10/10
1.9 ± 0.1
10/10
Hyperplasia with corniﬁcation 5.0 ± 0.0
10/10
4.3 ± 0.6
8/9
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
4.7 ± 0.3
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
Vocal cords, upper medial
region
Squamous metaplasia without
corniﬁcation
5.0 ± 0.0
10/10
4.8 ± 0.1
9/9
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
4.7 ± 0.2
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
Squamous metaplasia with
corniﬁcation
4.7 ± 0.2
10/10
4.3 ± 0.4
9/9
4.4 ± 0.3
10/10
4.7 ± 0.3
10/10
3.9 ± 0.5
10/10
4.8 ± 0.1
10/10
4.8 ± 0.1
10/10
Pseudo-stratiﬁed
epithelium
Squamous metaplasia without
corniﬁcation
5.0 ± 0.0
10/10
5.0 ± 0.0
9/9
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
Squamous metaplasia with
corniﬁcation
5.0 ± 0.0
10/10
5.0 ± 0.0
9/9
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
5.0 ± 0.0
10/10
Vocal folds Squamous epithelium Hyperplasia without corniﬁcation 1.1 ± 0.1
10/10
1.0 ± 0.0
9/9
1.0 ± 0.0
10/10
1.0 ± 0.0
10/10
1.2 ± 0.1
10/10
1.0 ± 0.0
10/10
1.0 ± 0.0
10/10
Hyperplasia with corniﬁcation 4.6 ± 0.4
10/10
4.8 ± 0.1
9/9
3.3 ± 0.6
8/10⁄
4.0 ± 0.6
9/10
3.8 ± 0.5
9/10
4.5 ± 0.2
10/10
4.4 ± 0.3
10/10
Tracheal
bifurcation
Respiratory epithelium Squamous metaplasia without
corniﬁcation
0.7 ± 0.4
3/9
1.9 ± 0.7
5/9
0.4 ± 0.4
1/10
1.9 ± 0.6
6/10
1.8 ± 0.6
5/10
0.6 ± 0.2
4/9
2.2 ± 0.5
8/10⁄
Left lung Respiratory epithelium Goblet cell hyperplasia 1.4 ± 0.4
7/10
2.4 ± 0.4
8/8
0.9 ± 0.2
7/10
0.9 ± 0.5
4/10
0.9 ± 0.4
5/9
0.9 ± 0.4
5/10
2.1 ± 0.5
9/10
Alveoli Alveolar macrophages without
pigmentation
1.0 ± 0.0
10/10
1.0 ± 0.0
8/8
1.0 ± 0.0
10/10
1.0 ± 0.0
10/10
1.2 ± 0.1
10/10
1.1 ± 0.1
10/10
1.1 ± 0.1
10/10
Alveolar macrophages with
pigmentation
1.2 ± 0.1
10/10
1.1 ± 0.1
8/8
1.2 ± 0.1
10/10
1.6 ± 0.3
10/10
1.4 ± 0.2
10/10
1.5 ± 0.2
10/10
1.6 ± 0.2
10/10
Pigmented macrophage nests 1.6 ± 0.6
7/10
0.5 ± 0.2
4/8
0.6 ± 0.2
5/10
0.7 ± 0.2
7/10
1.0 ± 0.3
7/10
1.1 ± 0.4
7/10
1.2 ± 0.5
5/10
Granulocytes/lymphocytes 0.7 ± 0.3
5/10
0.4 ± 0.2
3/8
0.3 ± 0.2
3/10
0.6 ± 0.2
6/10
0.3 ± 0.2
3/10
0.4 ± 0.2
4/10
0.7 ± 0.3
4/10
Remarks: Only endpoints are shown that are responsive to mainstream smoke when compared to the fresh air (sham) exposed rats. Comparison to control: * and ** indicate
statistically different to control cigarette group, p 6 0.05 and p 6 0.01, respectively.
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ferences between the control and test cigarette groups.
Based on the histopathology assessment of the respiratory tract,
there was no evidence for an inﬂuence of the ingredient Mix A or
Mix B on the biological activity of inhaled cigarette MS. Some
responses in the respiratory tract of the Mix C groups were slightly
higher in the upper respiratory tract organs at the end of the 90-day
inhalation period within perspective of the total number of
endpoints evaluated. However, because of the known inherentvariability of these endpoints in rats exposed to MS from the refer-
ence cigarette 2R4F, and the limited number of statistically signiﬁ-
cant differences between Mix C groups and the control group
(almost entirely limited to female rats in nose level 1 and considered
as being moderate increases only), these changes were not consid-
ered biologically relevant as they were sporadic and inconsistent.
After the post-inhalation period, the relative recovery of histopa-
thological ﬁndings was similar among all smoke-exposed groups
except for a few individual endpoints. Overall, the data indicate that
Fig. 3. Frequency of micronucleated reticulocytes in peripheral blood (MnRET) (A)
and of micronucleated polychromatic erythrocytes in bone marrow (MnPCE) (B) of
male rats exposed to fresh air (sham) and MS of the control and test cigarettes
(mean ± standard error, N = 8 rats per group).
S88 H. Schramke et al. / Regulatory Toxicology and Pharmacology 70 (2014) S81–S89the addition of ingredientMix A, Mix B orMix C did not increase the
overall biological activity of the cigarette MS tested in a 90-day
inhalation study at an exposure regimen of 6 h/day, 7 days/week,
at 200 lg/l TPM.
In general, the phenotypic alterations observed in the 90-day
inhalation study in rats exposed to MS from experimental kretek
cigarettes were similar to those observed in previous 90-day inha-
lation studies assessing MS from typical American-blended test
cigarettes (Carmines and Gaworski, 2005; Carmines et al., 2005;
Gaworski et al., 2008a,b, 2009, 2010, 2011; Lemus et al., 2007;
Vanscheeuwijck et al., 2002). Following the strict protocol of an
OECD study, with a particular emphasis on the respiratory tract,
no new ﬁndings have been observed for the various endpoints
investigated in the in vivo inhalation study for MS from the exper-
imental kretek cigarettes in contrast to the experimental short-
term inhalation exposure studies in rats with kretek cigarettes
reported before (Clark, 1989, 1990). Of the 350 ingredients tested
in experimental kretek cigarettes in this study, 260 ingredients
have been toxicologically assessed as single ingredients and/or in
mixes applied to experimental American-blended cigarettes. These
previous studies using experimental American-blended cigarettes
in general have concluded that the addition of ingredients did
not increase the inherent toxicity of cigarette MS as has been
shown now for typical kretek cigarettes as well. Mixes of ingredi-
ents have been tested in conventional typical American-blended
cigarette designs (Baker et al., 2004; Carmines, 2002; Gaworski
et al., 1998; Renne et al., 2006), and studies have consistently con-
cluded that the inclusion of ingredients as used in the manufacture
of cigarettes do not change the type or extent of toxicological
effects observed in rats exposed to cigarette MS.
Exposure of male rats to MS from test cigarettes containing
either ingredients Mix A, Mix B, or Mix C at a low or a high target
level did not increase the proportions of micronucleated cells in
peripheral blood and in bone marrow over the proportion of micro-
nucleated cells in the control cigarette group. Furthermore, no rel-
evant differences in the proportion of micronucleated reticulocytes
and polychromatic erythrocytes were seen between the smoke-
exposed groups and the sham-exposed groups. Therefore, MS from
these cigarettes is considered not to be clastogenic/aneugenic in
the in vivo micronucleus assay. These ﬁndings have been observed
consistently for MS from typical experimental American-blended
cigarettes in former studies with rats (Carmines and Gaworski,
2005; Carmines et al., 2005; Gaworski et al., 2008b; Lee et al.,
1990; Van Miert et al., 2008). An increase in the frequency of
micronuclei in bone marrow polychromatic erythrocytes has been
observed in rats exposed to a model of environmental cigarette
smoke compared to control animals (Balansky et al., 2000). In mice,
exposure to mainstream cigarette smoke has been shown both to
increase (Balansky et al., 1988, 1999, 2000) and not to increase
(Brown et al., 1997) the formation of micronuclei in bone marrow
polychromatic erythrocytes and in peripheral blood normochro-
matic erythrocytes. Although it has been shown in previous studies
and in this study that the in vivomicronucleus assay did in general
not detect effects induced by MS from conventional cigarettes and
from kretek cigarettes, respectively, as part of a standard test bat-
tery, it may play a role in assessing possible adverse effects related
to new cigarette products modiﬁcations, in this case, ingredient
mixes.
Results from this study indicated that the addition of ingredi-
ents to the ﬁller of typical kretek cigarettes did not change signif-
icantly the overall in vivo toxicity proﬁle of MS from these
cigarettes, even at the exaggerated levels used. The smoke chemis-
try analysis of the cigarettes containing the three ingredient mixes
at a low or a high target level revealed several differences in the
smoke composition, both towards higher and lower smoke yields
(Roemer et al., 2014a). These differences in smoke chemistryobviously did not affect the biological endpoints investigated in
this 90-day inhalation study and 4-day in vivo micronucleus assay
in rats. In addition, the in vitro cytotoxicity and mutagenicity/geno-
toxicity results (Roemer et al., 2014a) are consistent with the con-
clusion drawn from these two in vivo studies.
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